StreetInsider.com News Articles

Form 4 BIO-RAD LABORATORIES, For: Sep 01 Filed by: BARRY JAMES

Thu, 03 Sep 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260903/27026191.html

Form 4 BIO-RAD LABORATORIES, For: Sep 01 Filed by: BARRY JAMES

Thu, 03 Sep 2026 17:41:00 -0400

si-local-file:///var/storage/secattach/20260903/27026191.html

Form 4 BIO-RAD LABORATORIES, For: Sep 01 Filed by: Allison Schwartz

Thu, 03 Sep 2026 17:39:00 -0400

si-local-file:///var/storage/secattach/20260903/27026182.html

Form 4 BIO-RAD LABORATORIES, For: Sep 01 Filed by: Allison Schwartz

Thu, 03 Sep 2026 17:39:00 -0400

si-local-file:///var/storage/secattach/20260903/27026182.html

Form 4 BIO-RAD LABORATORIES, For: Sep 01 Filed by: SCHWARTZ NORMAN D

Thu, 03 Sep 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260903/27026169.html

Form 4 BIO-RAD LABORATORIES, For: Sep 01 Filed by: SCHWARTZ NORMAN D

Thu, 03 Sep 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260903/27026169.html

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

Mon, 31 Aug 2026 09:00:00 -0400

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time).

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

Mon, 31 Aug 2026 09:00:00 -0400

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

Mon, 31 Aug 2026 09:00:00 -0400

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

Mon, 31 Aug 2026 09:00:00 -0400

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a

iMDx posts Q2 loss as FDA review of GraftAssureDx continues

Mon, 10 Aug 2026 16:07:46 -0400

Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) reported a net loss of $11.3 million, or $0.31 per share, for the second quarter ended June 30, 2026, as the Nashville-based company continues to await FDA marketing authorization for its GraftAssureDx transplant diagnostic kit.

Revenue for the quarter was approximately $239,000, down from $518,000 in the same period a year earlier. Gross profit was $157,000, representing a gross margin of 65.7%. Operating expenses totaled $11.6 million, including a non-cash charge of $2.3 million related to a change in the fair value of contingent consideration and $661,000 in stock-based compensation. On a non-GAAP basis, the

iMDx posts Q2 loss as FDA review of GraftAssureDx continues

Mon, 10 Aug 2026 16:07:46 -0400

iMDx posts Q2 loss as FDA review of GraftAssureDx continues

Mon, 10 Aug 2026 16:07:46 -0400

iMDx posts Q2 loss as FDA review of GraftAssureDx continues

Mon, 10 Aug 2026 16:07:46 -0400

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx